维普期刊资源整合服务平台（V6.5）

47篇 您的检索式：作者名="Feagan B"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial显示文摘	Stephen B Hanauer Brian G Feagan Gary R Lichtenstein Lloyd F Mayer S Schreiber Jean Frederic Colombel Daniel Rachmilewitz Douglas C Wolf Allan Olson Weihang Bao Paul Rutgeerts	2002	The Lancet2002，，9317：	6
2	Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial 显示文摘	Sandborn W J Schreiber S Feagan B G	2011	Clin Gastroenterol Hepatol2011，9，8：	1
3	Infliximab forinduction and maintenance therapy for ulcerative colitis显示文摘	RUTGEERTS P SANDBORN W J FEAGAN B G	2005	NEngl J Med2005，353，23：	1
4	Infliximab for induction and maintenance therapy for ulcerative colitis显示文摘	Rutgeerts P Sandborn W J Feagan B G		New England Journal of Medicine0，，：	1
5	Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty显示文摘	FEAGAN B G WONG C J KIRKLEY A	2000	Ann Intern Med2000，33，：	1
6	Tacrolimus for the treatment of fistulas in patients with crohn’s disease: a randomized, placebo-controlled trial显示文摘	William J Sandborn Daniel H Present Kim L Isaacs Douglas C Wolf Eugene Greenberg Stephen B Hanauer Brian G Feagan Lloyd Mayer Therese Johnson Joseph Galanko Christopher Martin Robert S Sandler	2003	Gastroenterology2003，，2：	1
7	Certolizumab pegol for the treatment of Crohns disease 显示文摘	SANDBORN W J FEAGAN B G STOINOV S	2007	N Engl J Med2007，357，3：	1
8	A rev- iew of activity indices and efficacy end points for clinical trims of medical therapy in adults with ulcerative colitis 显示文摘	DHAENS G SANDBORN W J FEAGAN B G	2007	Gastroenterology2007，132，2：	1
9	Mainte- nance infliximab for Crohn's disease:the ACCENT I ran- domised trial 显示文摘	Hanauer S B Feagan B G Lichtenstein G R	2002	Lancet2002，359，9317：	1
10	Vedolizumab asinduction and maintenance therapy for ulcerative co!itis显示文摘	Feagan B G Rutgeerts P Sands B E	2013	NEngl J Med2013，369，8：	1
11	Treatment of ulcerative colitis with a humanized antibody to the alphadbeta7 integrin显示文摘	Feagan B Greenberg G Wild G	2005	N Engl J Med2005，352，：	1
12	Maintenance infliximab for Crohn's Disease:the ACCENT I Randomised Trial显示文摘	Hanauer S B Feagan B G Lichtenstein G R at a1	2002	Lancet2002，359，9317：	1
13	Cyclosporine for induction of remission in Crohn' s disease显示文摘	McDonald J Feagan B Jewell D	2005	Cochrane Database Syst Rev2005，，2：	1
14	Evidence based Gastroenterologiy and heapatology显示文摘	MeDonald J Burroughs A Feagan B	1999	BM J1999，，：	1
15	Infliximab for induction and maintenance therapy for ulcerative colitis显示文摘	Rutgeerts P Sandbom W J Feagan B G	2005	N Engl J Med2005，353，23：	1
16	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial显示文摘	Hanauer S B Feagan B G Lichtenstein G R	2002	Lancet2002，359，9317：	1
17	A randomized,double-blind,placebo-contralled,multi-center trial of the engineered human antibody to TNF(CDP571) for steroid sparing znd maintenance of remission in patients with steroid-dependent Crohn'sdisease显示文摘	Feagan BG Sandborn WJ Baker J Comineli F Sutherland LR Elson C Salzberg B Archambault A Bernstein C Lichtenstein G Heath PK Hanauer SB	2000	Gastroenterology2000，118，：	1
18	AGA technical review on perianal Crohn’s disease显示文摘	William J Sandborn Victor W Fazio Brian G Feagan Stephen B Hanauer	2003	Gastroenterology2003，，5：	1
19	Certolizumab pegol,a monthly subcutaneously administered Fc-free anti-TNFalpha,improves health-related quality of life in patients with moderate to severe Crohn's disease显示文摘	Rutgeerts P Schreiber S Feagan B		0，，：	1
20	Infliximab for induction and maintenance therapy for ulcerative colitis 显示文摘	Rutgeerts P Sandborn W J Feagan B G	2005	N Engl J Med2005，353，23：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示